X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (204) 204
index medicus (179) 179
oncology (153) 153
male (111) 111
female (110) 110
cancer (91) 91
treatment-related mortality (90) 90
chemotherapy (84) 84
hematology (83) 83
middle aged (82) 82
aged (80) 80
care and treatment (79) 79
adult (64) 64
treatment outcome (53) 53
risk factors (51) 51
analysis (47) 47
survival (44) 44
health aspects (39) 39
transplantation (37) 37
radiotherapy (36) 36
research (36) 36
therapy (36) 36
toxicity (34) 34
child (33) 33
prognosis (32) 32
article (31) 31
hematology, oncology and palliative medicine (31) 31
mortality (31) 31
adolescent (30) 30
antineoplastic agents - adverse effects (30) 30
treatment-related toxicity (30) 30
bone-marrow-transplantation (29) 29
patient outcomes (29) 29
retrospective studies (29) 29
aged, 80 and over (28) 28
antineoplastic agents - therapeutic use (28) 28
cancer patients (28) 28
medicine & public health (28) 28
risk (28) 28
incidence (27) 27
children (26) 26
double-blind (25) 25
immunology (25) 25
patients (25) 25
quality-of-life (25) 25
radiology, nuclear medicine & medical imaging (25) 25
disease-free survival (24) 24
radiation (24) 24
complications and side effects (23) 23
meta-analysis (23) 23
leukemia (22) 22
quality of life (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
clinical trials (21) 21
hematopoietic stem cells (21) 21
pediatrics (21) 21
stem-cell transplantation (21) 21
survival analysis (21) 21
young adult (21) 21
child, preschool (20) 20
survival rate (20) 20
versus-host-disease (20) 20
drug therapy (19) 19
hematopoietic stem cell transplantation - adverse effects (19) 19
neoplasm staging (19) 19
neoplasms - drug therapy (19) 19
stem cells (19) 19
tumors (19) 19
infant (18) 18
immunotherapy (17) 17
randomized controlled trials as topic (17) 17
acute myeloid-leukemia (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
cell lung-cancer (16) 16
outcomes (16) 16
cancer therapies (15) 15
follow-up studies (15) 15
pharmacology & pharmacy (15) 15
stem cell transplantation (15) 15
acute lymphoblastic-leukemia (14) 14
body-mass index (14) 14
cohort studies (14) 14
radiation-therapy (14) 14
time factors (14) 14
transplantation conditioning - methods (14) 14
transplantation, homologous (14) 14
treatment-related lymphopenia (14) 14
antimitotic agents (13) 13
antineoplastic agents (13) 13
breast-cancer (13) 13
carcinoma (13) 13
clinical trials as topic (13) 13
leukemia, lymphocytic, chronic, b-cell - therapy (13) 13
management (13) 13
medicine (13) 13
phase-iii trial (13) 13
remission induction (13) 13
studies (13) 13
abridged index medicus (12) 12
acute myeloid leukemia (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Critical Reviews in Oncology / Hematology, ISSN 1040-8428, 05/2019, Volume 137, pp. 115 - 122
Sunitinib, a tyrosine kinase inhibitor, is widely used in several malignancies. However, the association between sunitinib administration and fatal adverse... 
Fatal adverse events | Sunitinib | Trial sequential analysis | Cancer | METAANALYSIS | EFFICACY | TREATMENT-RELATED MORTALITY | COMBINATION | SORAFENIB | TRIAL SEQUENTIAL-ANALYSIS | RENAL-CELL CARCINOMA | PHASE-III TRIAL | CAPECITABINE | ONCOLOGY | HEMATOLOGY | ERLOTINIB | Tyrosine | Medical colleges | Cancer patients | Care and treatment
Journal Article
Journal Article
Frontiers in Pharmacology, ISSN 1663-9812, 10/2019, Volume 10
Background: Immune checkpoint blockade has revolutionized the treatment of multiple malignancies. Currently, however, the effect is not universal, with... 
antiangiogenic monoclonal antibody | immune checkpoint inhibitor | tyrosine kinase inhibitor | concurrent therapy | treatment-related adverse event | immune-related adverse event
Journal Article
Zhongguo Fei Ai Za Zhi, ISSN 1009-3419, 10/2019, Volume 22, Issue 10, pp. 671 - 675
近年来,免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)已成为肿瘤治疗的突破性进展之一。但随着ICIs的广泛应用,这类药物所导致的免疫相关副反应(immune-related adverse events,... 
Drugs | Immunotherapy | Rheumatoid arthritis | Rheumatology | TNF inhibitors | Tumor necrosis factor-TNF | Metastasis | Cancer therapies | Apoptosis | Immune checkpoint inhibitors | Immune-related adverse events | Treatment | Rheumatic disease
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 03/2017, Volume 13, Issue 3, pp. e223 - e230
Purpose Although patient safety is a priority in oncology, few tools measure adverse events (AEs) beyond treatment-related toxicities. The study objective was... 
RECORDS | ONCOLOGY | HARVARD MEDICAL-PRACTICE | HARM | PATIENT SAFETY | Medical Oncology - methods | Humans | Middle Aged | Male | Quality Improvement | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Longitudinal Studies | Drug-Related Side Effects and Adverse Reactions - diagnosis | Cohort Studies | Index Medicus
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2018, Volume 12, pp. 3043 - 3049
Journal Article
American Health and Drug Benefits, ISSN 1942-2962, 2018, Volume 11, Issue 7, pp. 334 - 343
Immunotherapies and targeted therapies have drastically improved survival in metastatic melanoma, but they can cause a range of adverse events (AEs).... 
Metastatic melanoma | Economic burden | Adverse events | Targeted therapy | Immunotherapy | Elderly patients | Treatment-related costs | elderly patients | targeted therapy | metastatic melanoma | immunotherapy | treatment-related costs | adverse events | economic burden | Business
Journal Article
International Journal of Cancer, ISSN 0020-7136, 08/2014, Volume 135, Issue 4, pp. 763 - 773
Journal Article
Journal of Evaluation in Clinical Practice, ISSN 1356-1294, 2019
Clinical pharmacy services are vital in the prevention of adverse drug events (ADEs) in clinical practice, extending beyond the hospital to chronic disease... 
cost avoidance | clinical pharmacy | Jordan | outpatient | treatment-related problems | cost saving
Journal Article
Joint Bone Spine, ISSN 1297-319X, 2019, Volume 86, Issue 6, pp. 715 - 723
70 years after their first use, low-dose glucocorticoids are a common part of pharmacological rheumatoid arthritis treatment. This is due to their well-proven... 
Treatment-related adverse events | Glucocorticoids | Long-term outcome Glucocorticoid Toxicity Index | Toxicity | Modified-release prednisone
Journal Article